{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Women-Only&page=3",
    "query": {
      "intervention": "Women-Only",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 1543,
    "total_pages": 155,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Women-Only&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Women-Only&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T17:03:52.740Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02530710",
      "title": "A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Q203",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Qurient Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 56,
      "start_date": "2015-08",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2016-12-06",
      "last_synced_at": "2026-10-15T17:03:52.740Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02530710"
    },
    {
      "nct_id": "NCT00201448",
      "title": "Evaluation of the Safety and Immune Responses of the Towne Strain of CMV in Seronegative Women",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Cytomegalovirus Infections"
      ],
      "interventions": [
        {
          "name": "Hepatitis A Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Towne CMV Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 82,
      "start_date": "2007-06",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2016-05-30",
      "last_synced_at": "2026-10-15T17:03:52.740Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00201448"
    },
    {
      "nct_id": "NCT06667713",
      "title": "ENTRUST - Economic Navigation and Strengthening to Realize Unrestricted Services for Transgender Women",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Substance Use Disorder (SUD)",
        "HIV"
      ],
      "interventions": [
        {
          "name": "ENTRUST - substance use and HIV counseling and goal setting with economic empowerment and photovoice training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "SBIRT-T only",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Central Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2024-11-01",
      "completion_date": "2025-03-14",
      "has_results": false,
      "last_update_posted_date": "2025-05-20",
      "last_synced_at": "2026-10-15T17:03:52.740Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06667713"
    },
    {
      "nct_id": "NCT07079761",
      "title": "Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer.",
          "type": "DRUG"
        },
        {
          "name": "Matching IV Placebo",
          "type": "OTHER"
        },
        {
          "name": "Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 96,
      "start_date": "2025-08-04",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-05",
      "last_synced_at": "2026-10-15T17:03:52.740Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07079761"
    },
    {
      "nct_id": "NCT02219789",
      "title": "Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Estrogen Receptor Positive",
        "Progesterone Receptor Positive",
        "Recurrent Breast Carcinoma",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Alisertib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2014-12-05",
      "completion_date": "2018-10-01",
      "has_results": false,
      "last_update_posted_date": "2018-10-03",
      "last_synced_at": "2026-10-15T17:03:52.740Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02219789"
    },
    {
      "nct_id": "NCT01654068",
      "title": "Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Vertebral Metastasis"
      ],
      "interventions": [
        {
          "name": "Conformal High Dose Intensity Modulated Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Ronald McGarry",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2009-12-09",
      "completion_date": "2016-09-08",
      "has_results": true,
      "last_update_posted_date": "2019-04-19",
      "last_synced_at": "2026-10-15T17:03:52.740Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01654068"
    },
    {
      "nct_id": "NCT01588379",
      "title": "Mothers and Girls Dancing Together Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Physical Activity"
      ],
      "interventions": [
        {
          "name": "Girls and mothers Afro-centric dance program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Girls, alone",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Newsletter",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of Massachusetts, Amherst",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "11 Years",
        "sex": "FEMALE",
        "summary": "7 Years to 11 Years · Female only"
      },
      "enrollment_count": 152,
      "start_date": "2013-01",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-10-15T17:03:52.740Z",
      "location_count": 1,
      "location_summary": "Springfield, Massachusetts",
      "locations": [
        {
          "city": "Springfield",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01588379"
    },
    {
      "nct_id": "NCT06612879",
      "title": "A Study to Find Out How BIIB141 (Omaveloxolone) Moves From the Blood Into the Breastmilk of Healthy Women Who Are Breastfeeding or Pumping Milk",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Omaveloxolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2024-10-18",
      "completion_date": "2025-04-08",
      "has_results": false,
      "last_update_posted_date": "2025-04-22",
      "last_synced_at": "2026-10-15T17:03:52.740Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06612879"
    },
    {
      "nct_id": "NCT06679413",
      "title": "A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Study Participants"
      ],
      "interventions": [
        {
          "name": "midazolam",
          "type": "DRUG"
        },
        {
          "name": "metformin",
          "type": "DRUG"
        },
        {
          "name": "bupropion",
          "type": "DRUG"
        },
        {
          "name": "fenfluramine HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB BIOSCIENCES, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 22,
      "start_date": "2024-12-04",
      "completion_date": "2025-06-12",
      "has_results": true,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-15T17:03:52.740Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06679413"
    },
    {
      "nct_id": "NCT03856515",
      "title": "Gender Differences in Switching From Smoking Regular Cigarettes to E-Cigarettes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cigarette Smoking-Related Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nicotine Replacement",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Electronic Cigarette",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 169,
      "start_date": "2022-06-02",
      "completion_date": "2026-01-07",
      "has_results": true,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-10-15T17:03:52.740Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03856515"
    }
  ]
}